Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Avacopan
Avacopan is a substance that blocks part of the immune system to reduce inflammation in certain autoimmune blood vessel diseases.
Azathioprine
Azathioprine is a substance that suppresses the immune system to prevent organ rejection and treat autoimmune diseases.
Cyclophosphamide Monohydrate
Cyclophosphamide monohydrate is an anti-cancer substance used to treat various cancers and some serious autoimmune diseases.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Amg 569

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
UZ Leuven
Pediatric Rheumatology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Pediatric Rheumatology
Ledeberg, Belgium
Vseobecna Fakultni Nemocnice V Praze
Clinic of Pediatrics and Hereditary Disorders of Metabolism 1 LF and VFN
Prague, Czechia

Sponsor: Amgen Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.